Illumina CEO Jay Flatley tells Xconomy's Luke Timmerman that for a long time there was no innovation in the industry until the advent of next-gen sequencing which caused "huge amount of money" to be invested in the space. Currently, Flatley considers Life Technologies to be Illumina's primary competitor, but says his company is "way ahead" in terms of market share.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.